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Abstract
Background: Lung cancer is the leading cause of cancer deaths worldwide. Surgery, radiotherapy at conventional
and high dose and chemotherapy are the mainstay for lung cancer treatment. Insufficient migration and activation
of tumour specific effector T cells seem to be important reasons for inadequate host anti-tumour immune response.
Ionizing radiation can induce a variety of immune responses. The goal of this randomized trial is to assess if
a preoperative single fraction low dose radiation is able to improve anti-tumour immune response in operable early
stage lung cancer.
Methods/Design: This trial has been designed as an investigator-initiated, prospective, randomized, 2-armed
phase II trial. Patients who are candidates for elective resection of early stage non-small cell lung cancer will
be randomized into 2 arms. A total of 36 patients will be enrolled. The patients receive either 2 Gy or no
radiation prescribed to their primary tumour. Radiation will be delivered by external beam radiotherapy using
3D radiotherapy or intensity-modulated radiation technique (IMRT) 7 days prior to surgical resection. The primary
objective is to compare CD8+ T cell counts detected by immunohistochemistry in resected tumours following
preoperative radiotherapy versus no radiotherapy. Secondary objectives include the association between CD8+ T cell
counts and progression free survival, the correlation of CD8+ T cell counts quantified by immunohistochemistry and
flow cytometry, local tumour control and recurrence patterns, survival, radiogenic treatment toxicity and postoperative
morbidity and mortality. Further, frequencies of tumour reactive T cells in blood and bone marrow as well as whole
blood cell transcriptomics and plasma-proteomics will be correlated with clinical outcome.
Discussion: This unique intervention combining preoperative low dose radiation and surgical removal of early stage
non-small cell lung cancer is designed to address the problem of inadequate host anti-tumour immune response. If
successful, this study may affect the role of radiotherapy in lung cancer treatment.
Trial registration: NCT02319408; Registration: December 29, 2014.
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Background
Lung cancer causes more deaths than colon, breast and
prostate cancer together [1]. Non-small cell lung cancer
is the most common type of lung cancer and accounts
for approximately 81 % of all cases of lung cancer [2].
Close to 58 % of patients with NSCLC present with lo-
cally advanced or metastatic disease (stages IIIB and IV)
at the time of diagnosis [3]. By then, the disease is gener-
ally incurable. Even in early stages of disease, the median
time to tumour relapse after complete surgical resec-
tion is two years. The 5-year survival rate is 73 % in
stage IA, 58 % in stage IB and 46 % in stage IIA. How-
ever, this rate drops to 36 % in stage IIB and 24 % in
stage IIIA [4].
Currently four cycles of adjuvant platin-based chemo-
therapy is recommended in patients with completely
resected stage II-IIIA NSCLC [5]. However, its adminis-
tration only provides a 5-year absolute survival benefit
of 4 % [6]. Moreover, due to medical comorbidities, age,
poor performance status or postoperative complications
a significant amount of patients is not eligible for adju-
vant chemotherapy [7].
The 5-year recurrence-free rate even in stage I NSCLC
is only about 75 % [8]. Therefore the development of
postoperative treatments represents a so far unmet med-
ical need for patients with resected stage I-IIA NSCLC
as well as for patients with stage IIB-IIIA NSCLC, which
will not be included into this study.
Radiotherapy (RT) is an important treatment modality
for localized tumours. RT typically induces primarily mi-
totic cell death but also leads to apoptosis [9] and complex
effects on the tumour microenvironment, which can fa-
cilitate homing of both antigen presenting cells and
effector T cells [10]. Sublethal doses of ionizing radi-
ation have been described to directly stimulate major
histocompatibility complex (MHC) expression that ren-
ders tumour cells more sensitive to detection and lysis
by specific T cells [11].
Tumour antigen specific cytotoxic and T helper cells
are spontaneously generated in many cancer patients
and provide the basis for T cell accumulation in tumour
tissue [12–22]. Increased tumour infiltration by endogen-
ous T cells has been associated with prognosis in several
solid cancer types [23]. In NSCLC the presence of tumour
infiltrating lymphocytes has been shown to be associated
with improved outcome [24–32]. However, T cell based
immunotherapies are limited by insufficient frequencies of
tumour infiltrating T cells in NSCLC [33].
RT may provide a local anti-tumour immune effect
and modulate the tumour microenvironment. Further-
more, preclinical work in murine models suggests that
local radiotherapy plus intratumoural syngeneic dendritic
cells (DC) injection can improve immunologic tumour
eradication [34].
In two other tumour entities, namely in resectable
liver metastases from colorectal cancer [35] and resect-
able pancreatic cancer [36] analogue studies are recruit-
ing with promising preliminary results [37].
In this trial the impact of preoperative low dose radi-
ation on immune response will be tested in lung cancer
patients with cN0 lymph nodes. Preoperative radiation is
commonly given before surgery for stage III lung cancer
as per the intergroup trial 0139. The latter randomized
controlled trial was conducted to test the value of sur-
gery after preoperative concurrent chemotherapy/45 Gy
radiotherapy for stage III N2 lung cancer. Patients
who underwent radical lobectomy compared to those
who received completion radiation up to 61 Gy
showed a better long term overall survival [38]. How-
ever, whether chemotherapy, radiation, surgery or a
combination of these treatments and which biological
mechanism contributed to the survival benefit re-
mains unclear. Our trial will focus on the biological
phenomena that may contribute to overcoming the
immunosuppressive processes that prevent an effect-
ive anti-tumour response.
While high radiation doses, ~20 Gy and above single
dose, are thought to induce immune response via necro-
sis or other mechanisms, low dose radiation, more than
0.5 Gy and less than 5 Gy, may evoke immune response by
polarization change of macrophages and subsequent T cell
invasion. Data from our earlier studies suggest that doses
around 2 Gy are sufficient to provoke a marked T cell inva-
sion in irradiated tumours [35, 36, 39]. Furthermore 2 Gy
is the standard single fraction dose in our clinical setting.
So far, no systematic clinical analysis has been performed
to investigate the immune stimulatory effect of low dose
radiotherapy in patients with NSCLC. Therefore, for both
biological and practical reasons, we suggest here to test the
hypothesis that a single 2 Gy fraction of external beam
radiation administered 1 week prior to lobectomy will
improve anti-tumour immune responses in patients with
resectable early stage non-small cell lung cancer.
Methods/design
Patient selection criteria
This single institutional trial focuses on patients with
operable early stage NSCLC. Patients scheduled for
elective lobectomy at Thoraxklinik Heidelberg, a special-
ized lung cancer hospital at Heidelberg Comprehensive
Cancer Center, may be enrolled in this study if all inclu-
sion criteria are fulfilled.
Potential immune-mediated diseases are exclusion cri-
teria. They include autoimmune diseases and other in-
flammatory and neurologic disorders that may have an
autoimmune aetiology [40]. The patient must be ex-
cluded if any exclusion criterion applies.
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Inclusion criteria
♦ Histologically proven clinical stage I to IIA pulmonary
adenocarcinoma
♦ Lung tumour is felt to be curatively resectable by the
treating physicians
♦ Sufficient pulmonary function for lobectomy
according to current guidelines [41]
♦ The patient is free of distant metastases as confirmed by
contrast-enhanced chest and upper abdomen CT-scan
and by contrast-enhanced CT or MRI of the brain
♦ Age 40 at the time of consent due to federal radiation
protection law
♦ In female patients of childbearing potential there must
be a negative pregnancy test
♦ ECOG performance status of 0,1, 2 or 3 at the time of
randomization
♦ Patients who the investigator believes can and will
comply with the requirements of this protocol
♦ Written informed consent according to ICH/GCP and
national/regional regulations
Exclusion criteria
♦ The patient shows clinical signs of pneumonia
♦ The patient receives immunosuppressive drugs
(alkylating agents, antimetabolites, methotrexate,
azathioprine, mercaptopurine, cytotoxic antibodies,
ciclosporin, tacrolimus, sirolimus, interferon,
mycophenolate, small biological agents)
♦ The patient receives oral or inhaled steroids on a
regular basis
♦ The patient has been diagnosed with a potential
immune mediated disease
♦ Elevated blood leukocyte count or erythrocyte
sedimentation rate [42]
♦ Pregnancy
♦ The patient has received any cancer specific treatment,
including radiotherapy, thermal ablation, hyperthermia,
immunotherapy, hormonal therapy or chemotherapy
♦ The patient is diagnosed with a concomitant
malignancy and/or has a history of malignancy within
the past five years or has had a malignancy that has
been in complete remission for less than 5 years
♦ The patient needs chronic long term oxygen therapy
♦ The patient has undergone splenectomy
♦ The patient is known to be HIV positive
♦ The patient has an uncontrolled bleeding disorder
♦ The patient received any anti-infectious vaccination in
the last 6 months
Trial design
This is a randomized phase II single centre trial compar-
ing the frequencies of tumour infiltrating CD8+ T cells
in early stage NSCLC patients receiving 2 Gy preopera-
tive radiotherapy versus no preoperative radiotherapy.
The randomization ratio is 1:1 (Fig. 1).
Procedures
Radiotherapy
Within the radiotherapy treatment arm patients will re-
ceive a single fraction of radiation on day 0 ± 2 days
prescribed to their primary tumours only which are going
to be removed later in the surgical procedure. The single
fraction radiation will be administered 7 ± 2 days prior to
operative tumour resection. After the adjustment of an
individual positioning device, computed tomography and,
if needed, magnetic resonance imaging (MRI) treatment
planning examinations are performed. After treatment
planning 3D radiotherapy or IMRT will be administered
using 6-megavolt linear acceleration (LINAC) photon
beams.
Safety aspects and adverse events
Adverse events (AEs) rarely occur in conventional radio-
therapy using considerably higher doses (e.g. 30 x 2 Gy
and higher versus 2 Gy in this trial) [43]. Similarly, a sin-
gle dose of more than 30 Gy is prescribed for small lung
tumours as definitive treatment in patients who are no
candidates for surgery with an equally low side effect
profile. Potential AEs usually occurring in conventional
radiotherapy at higher thresholds include acute and sub-
acute skin alterations like redness, temporarily coughing,
transient nausea or diarrhoea, and pneumonitis. Medica-
tion for symptomatic treatment, e.g. antitussive drugs, is
permitted. Chronic side effects upon conventional high
dose radiotherapy including lung fibrosis can be excluded
here given the low dose single fraction and healthy
tissue sparing technique. Thus no relevant toxicities
are expected.
Surgery
The operation is not a study procedure. Lobectomy
with systematic lymph node dissection is considered
the most effective treatment for early stage NSCLC [5].
After low dose radiotherapy on day 0 ± 2 days, surgery
will be performed on day 7 ± 2 days. In brief, patients
undergo general anaesthesia and endobronchial double-
lumen intubation. Blood pressure, heart rate, electro-
cardiographic trace, respiratory frequency and oxygen
saturation are monitored continuously throughout the
operation by an anaesthesiologist. The entire lung con-
sists of two lobes on the left and three lobes on the
right side. Thoracotomy refers to surgical opening of the
chest usually through the fourth or fifth intercostal space.
Vascular and bronchial structures at the level of the hilum
are prepared and resected along with the corresponding
lobe and lymph node containing fatty tissues. A radical
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systematic lymph node dissection accomplishes a standard
lobectomy procedure. In special cases video-assisted thor-
acic surgery (minimal-invasive; small incisions) may re-
place open thoracotomy (larger incision). However, there
is no difference between the methods in terms of tumour
manipulation or even tumour cell spread.
Accurate assessment of lymph node status is a key-
factor for staging of NSCLC and its surgical outcome.
Therefore in this study all patients undergoing standard
lobectomy via anterolateral thoracotomy or video-assisted
thoracoscopic surgery will receive radical mediastinal and
hilar lymphadenectomy [44] .
Timeline
Patient screening
Only patients with stage I-IIA NSCLC, who, in the opin-
ion of the investigators, are likely to meet all inclusion
and none of the exclusion criteria may be included in
this study on day −30 to day 0. All patients will be
staged with PET/CT. Lymph nodes with pathological
findings are routinely examined via bronchoscopy and
fine needle aspiration or mediastinoscopy. Only patients
that are clinically N0 will be enrolled. Patients should re-
ceive detailed information about the study and the study
procedures and should be proposed to sign the declar-
ation of informed consent to participate in the full study.
Registration, randomization and single fraction
radiotherapy
Patients will be registered on study and equally randomized
to the two treatment arms. Randomization will be done on
day −14 ± 2 days. Patients in the preoperative radiation
group will be seen on day −7 ± 2 days at the radiotherapy
Fig. 1 Enrolment, randomization, treatment of study participants and analysis
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department including radiation treatment planning and re-
ceive a single fraction radiation on day 0 ± 2 days.
Preoperative assessment
Each patient will be admitted to hospital on day 6 ± 2 days
(one day before surgery) and seen by an anaesthesiologist.
For study purposes bone marrow blood will be taken
under sterile conditions and local anaesthesia.
Surgery
Each patient will undergo standard lobectomy with radical
lymph node dissection on day 7 ± 2 days.
Postoperative visit
A patient will be considered to have completed the treat-
ment when he/she is deemed stable and has reached the
end of all scheduled study visits and the follow-up con-
tact. If no postoperative complications occur this may be
day 21 ± 7 days. Primary analysis of data and report of
these results will be conducted after the time when the
last patient completed the day 21 visit.
Long-term follow up
After the first postoperative visit patients will be seen on
an outpatient clinic basis every 3 months for 2 years and
then every 6 months for a total of 6 years. A secondary
analysis of long-term follow-up data will be conducted
to report on PFS and OS. The end of the entire study is
defined as when patient follow-up ends with last patient
completing study. The clinical trial is ended when data
analysis is completed and reported.
Ethical and legal considerations
The independent ethics committee of the University of
Heidelberg approved the final clinical trial protocol, the
patient information and informed consent sheets. Written
informed consent is obtained from each patient in oral
and written form before inclusion in the study. Patients
are informed about the strict confidentiality of their
personal data within this trial, but their pseudonymised
medical records may be reviewed for trial purposes by
authorized individuals other than their treating physician.
Participation to this trial is voluntary and patients are
allowed to refuse further participation at any time point
within the study. This trial is carried out in accordance
to the current Declaration of Helsinki (sixth revision,
2008), the principles of "Good Clinical Practice" (GCP),
and the Federal Data Protection Act. This study follows
the CONSORT guidelines and is registered at the
Clinical-Trials.gov protocol registration system (identifi-
cation number: NCT02319408).
Evaluation criteria/endpoints
Tumour infiltrating lymphocytes will be investigated as
described by Halama et al. [45]. Tissue specimens will be
immunohistochemically analysed for their infiltration of
CD8+ (primary endpoint), CD3+, CD4+, CD45RO+ and
Foxp3+ T cells (secondary endpoints) in tissue sections
from formalin-fixed, paraffin-embedded tissue.
Analysis of immunohistochemistry data
The number of stained immune cells will be counted
using a computerized image analysis system attached to
a personal computer. Complete microscopic images of
full tissue sections will be automatically obtained for
later automatic or manual visual analysis (virtual micros-
copy), allowing large-scale histologic evaluation with
high precision across the complete section. Thus, vary-
ing cell densities across the complete tissue section can
be measured objectively. In this analysis, the average cell
density across the measured region will be used for ana-
lysis. Manual evaluation of stained immune cells will be
conducted in duplicates without knowledge of the clini-
copathological data pathologist-blinded. Manual cell
counts will be reassessed with a specifically developed
software program to measure cell densities across a
given region of interest. This will be done to confirm the
manual cell counts, so that the automated quantification
application can be validated.
Other secondary endpoints
Other secondary endpoints are digitally versus manually
determined CD8+ T cell frequencies in resected NSCLC
tumours, frequencies of tumour reactive T cells in blood
and bone marrow before radiotherapy and after surgery,
changes in the level of proteins involved in immune re-
sponse in blood determined by ELISA and frequencies
of CD3+, CD4+, CD8+, CD45RO and Foxp3+ T cells in
resected NSCLC tumours determined by flow cytometry.
Depending on the availability of pre-enrolment har-
vested tumour tissue, the immune contexture of these
tumour biopsies will be compared to the post-radiation
samples obtained from surgery. Secondary analysis will
be conducted for progression free survival and overall
survival as secondary endpoints, which require long-
term follow-up of 6 years and will be performed and
reported subsequent to the primary analysis, as well as
other laboratory data derived from proteomic or tran-
scriptomic analyses. Whole blood transcriptomics will
be performed as described earlier [46]. Peripheral blood
samples will be obtained before radiation, at the time of
surgery, and the first visit of the patient at the radiation
oncology department, the total RNA will be extracted
from whole blood and the resulting expression profiles
will be correlated with the immune response and clinical
status of the patients. As for the proteome an array of
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20 cytokines with known roles in immune response will
be measured using a commercial protein array at the
same three time points. Tumour reactive T cells will be
determined in bone marrow aspirates by ELIPOT ana-
lysis. Bone marrow aspirates will be taken one to three
days before radiation and under anaesthesia before skin
incision.
Study design
This is a two-arm randomized phase II study to investigate
the influence of low dose radiotherapy on immune stimu-
latory effects in NSCLC. The protocol will accrue up to 36
response analysable patients. Patients will be randomized
to one of the following groups: 1. Control arm: no pre-
operative radiotherapy and 2. Experimental arm: 2 Gy
single fraction preoperative radiotherapy administered to
patients 7 days prior to surgery. The primary objective is
to assess the effect of local low dose radiotherapy on
tumour infiltrating CD8+ T cells (cells/mm2) as a surro-
gate measure for anti-tumour activity.
Randomization and stratifications
A block randomization will be conducted by computer
randomization. There is no stratification for randomization.
The randomization ratio is 1:1.
Sample size determination
Based on information of the study by Galon et al. [47] in
colorectal adenocarcinoma the presence of tumour infil-
trating T cells is associated with improved patient out-
come. Patients with a good prognosis had a mean of 600
CD8+ T cells/mm2 and patients with a bad prognosis
had a mean of 370 CD 8+ T cells/mm2. The standard de-
viation in both groups was 50 cells/mm2. Their analysis
further revealed a cut-off point: Patients with a fre-
quency of 300 tumour infiltrating CD8+ T-cells/mm2
had a significantly better prognosis. The difference be-
tween prognostic groups and identified threshold are
not assumed to translate directly to giving 2 Gy single
fraction preoperative radiotherapy in NSCLC, but the
standard deviation is used for sample size estimation in
the actual study.
The null hypothesis (H0) is that in patients with oper-
able NSCLC a single fraction low dose preoperative
radiotherapy does not increase the frequency of tumour
infiltrating CD8+ T cells. The alternative hypothesis (Ha)
used for power computation is that in patients with op-
erable NSCLC a single fraction low dose preoperative
radiotherapy increases the frequency of tumour infiltrat-
ing CD8+ T cells at least by 50 CD8+ T cells/mm2. For
both treatment arms we assume a standard deviation of
50 cells/mm2.
Given that the purpose of this study is to determine
whether preoperative radiotherapy should be studied
further, there is only one outcome of interest, superiority
of the experimental arm to the control. In this scenario,
we believe a one-sided testing framework is appropriate.
For this study we consider a one-sided test of the null
hypothesis that the true primary outcome is no different
between treatment and control with a type I error of
alpha = 0.05. In order to have 80 % power to reject the
null hypothesis if the alternative is true by using a one-
sided Wilcoxon rank sum test at level alpha = 0.05 the
required sample size for each treatment arm assuming
equal allocation is 15. A maximum loss of 15 % is con-
sidered due to poor tissue quality or technical problems.
Therefore a total of 36 patients will be enrolled and
equally randomized to the two study arms.
Data analysis
The frequency of CD8+ T cells (cells/mm2) in pa-
tients receiving 2 Gy preoperative radiotherapy versus
no preoperative radiotherapy will be compared using
the Wilcoxon rank sum test at a one-sided significant
level alpha = 0.05.
Descriptive statistics will be used to summarize the
distribution of CD8+ T cell counts by treatment arm
(mean, median, range, inter-quartile-range, and standard
deviation).
Descriptive statistics will be used to summarize the
correlation of the two the methods (IHC and flow cy-
tometry) of quantification of T cells. IHC will be used
for primary analysis for which sample size estimation
was performed. Distribution of T cell subsets (CD3+,
CD4+, CD45RO+, Foxp3+) and other secondary end-
points of immune response (frequencies of tumour re-
active T cells and protein levels) will be evaluated with
same analysis plan. Correlation in quantitative measures
of immune response will be evaluated using Spearman
rank correlation.
Distribution of progression free survival (PFS) and
overall survival (OS) will be estimated by the Kaplan-
Meier method. The treatment groups will be compared
with a stratified log rank test. The effect of frequencies
of tumour infiltrating CD8+ T cells on PFS and OS will
be analysed using Cox proportional hazards regression.
The relationship between measures of immune response
and PFS and OS will be explored in multivariable Cox
proportional hazard models including treatment arm as
covariate.
All secondary analyses will be exploratory using two-
sided significance levels alpha = 0.05.
Data management and quality assurance
The Department of Thoracic Surgery at Thoraxklinik
and the Molecular and Radiation Oncology Department
of the German Cancer Research Center and University
Hospital Heidelberg coordinate this trial. Data regarding
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T cell detection in blood and bone marrow of all patients
will be entered in a password-protected database at the
Department of Thoracic Surgery at Thoraxklinik and at
the German Cancer Research Center. The clinical and
laboratory data of all included patients will be centrally
collected in a password-protected database located at
the Department of Thoracic Surgery at Thoraxklinik.
Discussion
Non-small cell lung cancer (NSCLC) has still a poor prog-
nosis. Even in patients with radically operated stage I
NSCLC the 5-year recurrence-free rate only is about 75 %
[8]. The development of additional treatments represents
an unmet medical need for patients with completely
resected NSCLC. Preclinical cellular immunotherapeutic
approaches demonstrated the ability to reject solid tu-
mours by tumour specific T lymphocytes [15, 48], the
effectiveness of these approaches, however, could not be
translated into clinical trials so far. Insufficient migration
and activation of tumour infiltrating lymphocytes are con-
sidered the main reasons for inadequate host anti-tumour
immune response. Lung cancer is supposed to exhibit
a particular immunosuppressive microenvironment.
Low dose ionizing radiation stimulates a localized pro-
inflammatory milieu thereby modulating the tumour
microenvironment. The results of this trial could dem-
onstrate a beneficial immune related effect and suggest
low dose radiation to be a complementary neoadjuvant
component of immunotherapy prior to surgery in oper-
able NSCLC with only mild side effects in future. How-
ever this needs to be investigated in larger trials. The
goal of this randomized trial is to assess if combining
preoperative low dose radiation and surgical removal
of early stage non-small cell lung cancer will improve
host anti-tumour immune response. If successful, a
combination of immune modulatory treatments, such
as ionizing radiation and checkpoint inhibition may
help to reverse the process of immunosuppression in
NSCLC and could therefore be an integral treatment
strategy in NSCLC.
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